CD274 and Hodgkins lymphoma: Currently, with their wide application in melanoma, colorectal cancer, non-small-cell lung cancer, and Hodgkin’s lymphoma, ICI therapies targeting PD-1/PD-L1 show potential in treating relapsed BCa patients.